A Prognosis and Predicting Genetic Study of Lung Cancer

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital

About this trial

Lung cancer is a leading cause of cancer mortality among adults worldwide. The incidence rates of lung cancer among never smoking females in some parts of East Asia are among the highest in the world. The adenocarcinoma of lung being the most frequently identified histological type is more weakly associated with smoking, and often occurs in females and never-smokers. Although family history of lung cancer has been associated with histological subtypes, the inherited susceptibility factors that affect specific histology are unknown.

Genetic factors that determine individual predisposition to lung cancer have been identified via genome-wide association studies. These known common loci, however, explain only a small fraction of the familial risk of lung cancer. The hypothesis of this study is that there are genetic factors that confer inherited susceptibility among patients with primary non-small-cell lung cancer (NSCLC).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The patient's family (within third-degree relatives) has at least one diagnosed of primary non-small cell lung cancer.

The patient was diagnosed of primary non-small cell lung cancer at the age < 45 years old.

Disqualifiers

Patients without the diagnosis of primary non-small cell lung cancer.

Patients who are combined with other malignancy and ongoing chemotherapy / radiation therapy.

Patients combined with coagulopathy.

Trial population

Patients with diagnosis of primary non small cell lung cancer

Trial design

Design model

Family-based

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Genetic information of lung cancer patients

Collect study subjects' blood sample and analysis with Genome-wide SNP genotyping

Time frame
One week after the study subjects sign the permit of informed consents

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: